New combo therapy hopes to beat rare skin cancer
NCT ID NCT04930653
First seen Nov 01, 2025 · Last updated Jun 10, 2026 · Updated 28 times
Summary
This study tests whether combining two treatments—extracorporeal photopheresis (a light-based blood treatment) and mogamulizumab (a targeted antibody)—can better control erythrodermic cutaneous T-cell lymphoma, a rare skin cancer. About 34 adults with advanced stages of the disease will receive both therapies together. The goal is to see if the combination improves response rates and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEZARY SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic
RECRUITINGScottsdale, Arizona, 85259, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Winship Cancer Institute of Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.